Drug Trial News

RSS

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced.

24 Feb 2015

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin.

23 Feb 2015

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

23 Feb 2015

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe.

23 Feb 2015

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with mild vision problems, but one medication performed better for those with more serious vision loss.

23 Feb 2015

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).

23 Feb 2015

International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

Approximately 12,000 women are diagnosed with cervical cancer each year in the United States and another 4,000 die annually from the disease. However, most cervical cancers are preventable through immunization against the human papillomavirus (HPV). A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease.

21 Feb 2015

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.

21 Feb 2015

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).

20 Feb 2015

Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial

Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months.

20 Feb 2015

Researchers demonstrate clinical efficacy of gallopamil in severe asthma patients

A team of Inserm researchers from the Cardio-Thoracic Research Centre of Bordeaux (Inserm/University of Bordeaux and Bordeaux University Hospital) has demonstrated the clinical efficacy of gallopamil in 31 patients with severe asthma. This chronic disease is characterised by remodelling of the bronchi, which exacerbates the obstruction of the airways already seen in "classic" asthma.

20 Feb 2015

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.

20 Feb 2015

New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

A multinational study on a diverse group of women shows that a new nine-valent human papillomavirus (HPV) vaccine prevents infections and disease associated with the vaccine types, according to a paper published today in The New England Journal of Medicine.

19 Feb 2015

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research.

19 Feb 2015

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand--the first study to demonstrate that a vaccine can protect people from HIV infection.

19 Feb 2015

TB Alliance announces initiation of first human trial of new TB drug candidate

TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB drug candidate to begin a Phase 1 clinical trial since 2009.

19 Feb 2015

PAREXEL International expands clinical trial site alliance network

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients' clinical trials worldwide.

From Parexel 18 Feb 2015

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario.

18 Feb 2015

Drug Trial News

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

Palbociclib extends progression-free survival in advanced breast cancer patients

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial

Researchers demonstrate clinical efficacy of gallopamil in severe asthma patients

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

Study results pave way for new clinical trial for glioblastoma patients

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

TB Alliance announces initiation of first human trial of new TB drug candidate

PAREXEL International expands clinical trial site alliance network

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News